232 related articles for article (PubMed ID: 31402323)
1. Ibrutinib and rituximab for chronic lymphocytic leukaemia.
Stirrups R
Lancet Oncol; 2019 Sep; 20(9):e471. PubMed ID: 31402323
[No Abstract] [Full Text] [Related]
2. Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting.
Clin Adv Hematol Oncol; 2019 Jan; 17 Suppl 1(1):1-24. PubMed ID: 31545307
[No Abstract] [Full Text] [Related]
3. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
Shanafelt TD; Wang XV; Kay NE; Hanson CA; O'Brien S; Barrientos J; Jelinek DF; Braggio E; Leis JF; Zhang CC; Coutre SE; Barr PM; Cashen AF; Mato AR; Singh AK; Mullane MP; Little RF; Erba H; Stone RM; Litzow M; Tallman M
N Engl J Med; 2019 Aug; 381(5):432-443. PubMed ID: 31365801
[TBL] [Abstract][Full Text] [Related]
4. Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
Wierda WG
Clin Adv Hematol Oncol; 2019 Apr; 17(4):214-216. PubMed ID: 31188811
[No Abstract] [Full Text] [Related]
5. Selecting Frontline Therapy for CLL in 2018.
Jain N
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):242-247. PubMed ID: 30504317
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Woyach JA; Ruppert AS; Heerema NA; Zhao W; Booth AM; Ding W; Bartlett NL; Brander DM; Barr PM; Rogers KA; Parikh SA; Coutre S; Hurria A; Brown JR; Lozanski G; Blachly JS; Ozer HG; Major-Elechi B; Fruth B; Nattam S; Larson RA; Erba H; Litzow M; Owen C; Kuzma C; Abramson JS; Little RF; Smith SE; Stone RM; Mandrekar SJ; Byrd JC
N Engl J Med; 2018 Dec; 379(26):2517-2528. PubMed ID: 30501481
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
[TBL] [Abstract][Full Text] [Related]
8. Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
Huang SJ; Gerrie AS; Young S; Tucker T; Bruyere H; Hrynchak M; Galbraith P; Al Tourah AJ; Dueck G; Noble MC; Ramadan KM; Tsang P; Hardy E; Sehn L; Toze CL
Leuk Res; 2020 Apr; 91():106335. PubMed ID: 32114372
[TBL] [Abstract][Full Text] [Related]
9. Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis.
Xu Y; Fahrbach K; Dorman E; Baculea S; Côté S; Sanden SV; Diels J
J Comp Eff Res; 2018 May; 7(5):421-441. PubMed ID: 29210593
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib: searching for a partner drug.
Kater AP; Brown JR
Lancet Oncol; 2019 Jan; 20(1):3-5. PubMed ID: 30522966
[No Abstract] [Full Text] [Related]
11. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
12. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Brown JR; Hallek MJ; Pagel JM
Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
[TBL] [Abstract][Full Text] [Related]
13. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
[TBL] [Abstract][Full Text] [Related]
14. miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
Guinn D; Ruppert AS; Maddocks K; Jaglowski S; Gordon A; Lin TS; Larson R; Marcucci G; Hertlein E; Woyach J; Johnson AJ; Byrd JC
Leukemia; 2015 May; 29(5):1210-3. PubMed ID: 25486872
[No Abstract] [Full Text] [Related]
15. The efficacy of ibrutinib in the treatment of Richter syndrome.
Tsang M; Shanafelt TD; Call TG; Ding W; Chanan-Khan A; Leis JF; Nowakowski GS; Bowen D; Conte M; Schwager SM; Slager SL; Kay NE; Hanson CA; Parikh SA
Blood; 2015 Mar; 125(10):1676-8. PubMed ID: 25745187
[No Abstract] [Full Text] [Related]
16. Invasive aspergillosis with pulmonary and central nervous system involvement during ibrutinib therapy for relapsed chronic lymphocytic leukaemia: case report.
Peri AM; Bisi L; Cappelletti A; Colella E; Verga L; Borella C; Foresti S; Migliorino GM; Gori A; Bandera A
Clin Microbiol Infect; 2018 Jul; 24(7):785-786. PubMed ID: 29427802
[No Abstract] [Full Text] [Related]
17. Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Prescrire Int; 2016 Apr; 25(170):91. PubMed ID: 27186618
[No Abstract] [Full Text] [Related]
18. Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia.
Gauthier M; Durrieu F; Martin E; Peres M; Vergez F; Filleron T; Obéric L; Bijou F; Quillet Mary A; Ysebaert L
BMC Cancer; 2019 Aug; 19(1):809. PubMed ID: 31412798
[TBL] [Abstract][Full Text] [Related]
19. Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
Suzumiya J; Takizawa J
Int J Hematol; 2020 May; 111(5):642-656. PubMed ID: 32253666
[TBL] [Abstract][Full Text] [Related]
20. Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab.
Peragine N; De Propris MS; Intoppa S; Milani ML; Mariglia P; Mauro FR; Raponi S; Soddu S; Cuneo A; Rigolin GM; Del Giudice I; Foà R; Guarini A
Haematologica; 2020 Oct; 106(5):1500-1503. PubMed ID: 33054124
[No Abstract] [Full Text] [Related]
[Next] [New Search]
